In our ongoing exploration of UK-listed stocks through the lens of Stockopedia’s StockRanks, we’ve spotlighted companies ranging from deep-value rebounds like Currys to fast-improving small caps like Frontier Developments. Both companies have surged since the start of 2025, on renewed price and earnings momentum, and the markets’ broadening appeal for recovery plays.
Writes Keelan Cooper, Financial Analyst at Stockopedia
However, Hikma Pharmaceuticals LON:HIK offers a different kind of investment case, one grounded not in a dramatic turnaround story, but in the consistency of a disciplined compounder. With a StockRank of 88, underpinned by a strong Quality Rank of 89 and Momentum Rank of 87, this large-cap healthcare company combines operational prowess with a more defensive appeal. It is a steady, cash-generative business that may not be grabbing headlines, but its track record and fundamentals point to a company that is misunderstood, yet quietly building long-term value.
Source: Stockopedia
A resilient global player in generics
Hikma Hikma Pharmaceuticals develops, manufactures and markets a broad range of branded and generic pharmaceutical products across three main divisions: Injectables, Generics and Branded. Its Injectables segment, which supplies hospitals with critical care medicines such as anaesthetics, oncology treatments and anti-infectives, is a key profit driver.
The Generics division, focused primarily on the US market, offers a portfolio of non-branded oral and injectable products across a range of therapeutic areas. While this business has historically faced pricing pressure, recent years have seen a strategic shift towards complex generics and specialty products that offer better margins and durability.
Finally, the Branded division serves markets across the Middle East and North Africa (MENA), where Hikma enjoys strong brand recognition and local partnerships. This segment is more insulated from global pricing pressures and offers steady, cash-generative growth supported by demographic tailwinds and rising healthcare demand in emerging markets.
Source: Hikma Pharmaceuticals 2024 Annual Report
The group has delivered consistent revenue growth, with a compound annual growth rate of 7.5% over the past 6 years. Analysts now expect sales to reach $3.3 billion in 2025 and $3.5 billion in 2026, while earnings are forecast to grow by over 20% this year and 10.5% the next.
This is supported by a broad product pipeline and resilient demand across Hikma’s core markets. Its operational footprint, particularly its extensive domestic manufacturing base in the US, also insulates the business from international tariff risks that can impact cross-border pharmaceutical supply chains.
Source: Stockopedia
For income-focused investors, Hikma Hikma Pharmaceuticals pays a 3.26% forward dividend yield, with a strong record of dividend growth and a coverage ratio of over 2 times earnings (implying the dividend may even have room to grow further). While not as high-yielding as some FTSE defensives, the reliability of its distributions adds to its appeal.
Hikma Pharmaceuticals: Quality at the core
From a rules-based perspective, Hikma’s financial profile scores highly on the kind of quality metrics that Stockopedia’s system is designed to highlight. Its Return on Capital Employed (ROCE) of 19.3% reflects efficient use of capital, while operating margins of 19.3% indicate strong profitability relative to peers. When assessed through a systematic lens, these characteristics place the company firmly in the top quartile of the healthcare sector for quality attributes.
Source: Stockopedia
Hikma Hikma Pharmaceuticals may not be a rapid-growth story, but it stands out for its dependability. The company exhibits a high degree of predictability in its cash flows, product demand and capital allocation, traits that appeal strongly to long-term investors focused on stability and quality. This steady performance is further reflected in Hikma’s Piotroski F-Score, where it passes 7 out of 9 checks used to assess the improvement and resilience of a company’s financial position.
These checks highlight key strengths: Hikma is consistently profitable, generates solid operating cash flow, and actually produces more cash than it reports as profit, which is a positive sign of earnings quality.
Source: Stockopedia
Profitability is improving year-on-year at the moment, and long-term debt levels remain under control. It’s also increasing its ability to meet short-term obligations, pointing to strong financial health across the balance sheet.
Sentiment muted, but stabilising
Despite solid fundamentals under the surface, Hikma Hikma Pharmaceuticals share price performance has been relatively muted over a number of years now. In the last 12 months alone, the stock has underperformed the broader market by 3.6%, with weak relative strength across 1-, 3- and 6-month timeframes. The shares are currently trading 15.9% below their 52-week high, and short-term interest appears to be waning, with trading volumes down 37% over the past 10 days versus the three-month average.
Yet this weakness seems to reflect investor apathy, rather than clearly deteriorating fundamentals. Hikma’s earnings momentum seems to be what is currently supporting its investment profile. The company remains well covered by analysts, and the majority of broker ratings currently sit in the ‘Buy’ camp.
Source: Stockopedia
From a valuation perspective, the numbers look reasonable, particularly for a business of this quality. The shares trade on a forward PE ratio of 11.0, with a PEG ratio of 0.8, a level often associated with undervalued growth.
This kind of profile suggests a company in a holding pattern, with the market waiting for a clear catalyst. Whether it comes in the form of stronger-than-expected results, a strategic acquisition, or meaningful developments in the product pipeline, Hikma Hikma Pharmaceuticals may only need one well-received update to shift sentiment.
Interim results in August could reset the narrative
Investors may not have long to wait for the next potential catalyst. Hikma is scheduled to report its interim financial results for the six months to 30 June 2025 on Thursday, 7 August 2025. This update will provide a clearer picture of how the business is tracking against full-year guidance. If performance is ahead of expectations, or if management signals greater confidence in the outlook, it may be enough to trigger a rerating from current levels.
Equally, if the company were to report weaker-than-expected sales in the US generics market, with continued pricing pressure on its key products, or slowing growth in its Branded division in MENA, then this could shake investor confidence further. It’s also worth noting that, as a business with significant international exposure, the recent weakness in the US dollar is likely to have a negative impact on earnings.
In this regard, the upcoming results are likely to prove a critical point for investors not just to reflect on the headline numbers, but also the forward-looking commentary on margins, product pipeline progress and the company’s strategic focus in the face of global cost pressures.
Hikma Pharmaceuticals: Conclusion
Hikma Pharmaceuticals may not excite momentum traders in the short term, but it represents the kind of dependable, high-quality business that can anchor a portfolio. The fundamentals are sound, the valuation is fair, and the upcoming results may serve as a reminder of its long-term strengths.
We’ve explored 9 other companies in our Top Ten UK Stocks – July 2025 report that feature a diverse range of small, mid and large caps across 8 of the 10 major economic sectors. You can download the full report for free via the link below.
Download Stockopedia’s Top Stocks Report for free to view 9 other high-ranking UK shares
